Changes in Biomarkers of Exposure on Switching From a Conventional Cigarette to Tobacco Heating Products: A Randomized, Controlled Study in Healthy Japanese Subjects

Nathan Gale, Michael McEwan, Alison Eldridge, Ian M. Fearon, N. Sherwood, Edward Bowen, Simon McDermott, Emma Holmes, Andrew Hedge, Stuart Hossack, Louise Wakenshaw, James Glew, Oscar M. Camacho, Graham Errington, John McAughey, James J. Murphy, Chuan Liu, Christopher ProctorNicotine 2018 · DOI

TL;DR

This study investigated whether switching from conventional cigarettes to tobacco heating products (THPs) like glo™ and IQOS reduces exposure to harmful smoke constituents. The findings show significant reductions in biomarkers of exposure, comparable to quitting smoking entirely, suggesting THPs could be reduced-exposure products.

What Problem Does This Paper Address?

Smoking is a major contributor to numerous diseases, primarily due to exposure to toxic chemicals in cigarette smoke. While complete cessation is the ideal, many smokers struggle to quit. This has spurred interest in "reduced exposure" or "reduced risk" tobacco products (MRTPs) that might offer a less harmful alternative. However, demonstrating that these products actually lead to reduced exposure to toxicants in real-world use is crucial. This paper addresses the question of whether switching to newer tobacco heating products (THPs), which heat tobacco instead of burning it, demonstrably lowers exposure to key smoke toxicants compared to continued cigarette smoking or complete cessation.

Methods

This was a randomized, controlled, parallel-group, open-label clinical confinement study conducted in Japan. 180 healthy Japanese smokers were enrolled and randomized into six groups:

  • Control: Continue smoking conventional cigarettes.
  • THP Groups: Switch to either mentholated or non-mentholated variants of glo™ (a tobacco heating product) or a non-mentholated variant of IQOS/THS (an in-market comparator THP).
  • Cessation Group: Quit all nicotine and tobacco product use.

Participants underwent a 2-day baseline period smoking their usual cigarettes, followed by a 5-day exposure period using their assigned product or abstaining. Key measurements included:

  • Biomarkers of Exposure (BoE): 24-hour urine samples were collected to measure levels of 16 different chemicals (e.g., nicotine equivalents, NNAL, 1-hydroxypyrene) known to be present in cigarette smoke.
  • Exhaled Carbon Monoxide (eCO): Measured daily as an indicator of recent exposure to combustion products.

Statistical analysis focused on comparing BoE levels before and after the switching period (days 6-7) within each group and between groups.

Datasets

Not discussed in the paper. The study utilized data collected from the participants during the clinical trial.

Key Insights and Ideas

  • THPs show promise for reduced exposure: The core finding is that switching to THPs (glo™ and IQOS) significantly reduced exposure to a wide range of smoke toxicants, as measured by urinary biomarkers and eCO.
  • Comparable to quitting: Remarkably, the magnitude of these reductions in THP users was often similar to those observed in the group that completely quit smoking. This is a strong indicator of their potential as reduced-exposure products.
  • Nicotine intake maintained: Despite reduced exposure to other toxicants, nicotine intake (as measured by TNeq) remained stable or decreased in THP users, suggesting they were able to achieve their desired nicotine levels without the same level of toxicant exposure.
  • Safety and tolerability: The study reported that the THPs were generally safe and well-tolerated, with most adverse events being mild and unrelated to the study products.

Key Results

  • On day 5 after switching, urinary BoE (excluding nicotine) and eCO levels were significantly reduced (p < .05) by medians ranging from 20.9% to 92.1% compared to baseline across all THP and cessation groups.
  • Reductions in the glo™ groups were similar (p < .05) to quitting in many cases for most biomarkers.
  • For several key biomarkers (e.g., 3-HPMA, HMPMA, S-PMA, MHBMA, CEMA, 4-ABP, o-toluidine, 2-AN, total NNN, and HEMA), the changes from baseline in both glo™ THP groups were not significantly different from the cessation group.
  • eCO reductions in the non-menthol glo™ THP group, and total NNAL and 1-OHP in the menthol glo™ THP group, were also not significantly different from the cessation group.
  • While TNeq, AAMA, and GAMA showed significant reductions in THP groups, these changes were smaller than those observed in the cessation group.

Limitations and Future Work

  • Confinement vs. Real-World: The study was conducted in a controlled clinical setting. The authors acknowledge that this doesn't fully replicate real-world use, where other tobacco products might be available, and the observed exposure reductions might differ.
  • Short Study Duration: The 5-day study period limits conclusions about long-term exposure changes, particularly for biomarkers with longer elimination half-lives like NNAL. Longer-term studies are needed.
  • Limited Scope of Biomarkers: While 16 biomarkers were assessed, they represent only a subset of the thousands of chemicals in cigarette smoke. Conclusions about overall risk reduction are therefore limited.
  • Demographic Factors: The study did not explore potential relationships between biomarker changes and demographic variables like age or gender.
  • Future Work: The authors emphasize the need for longer-term studies to assess sustained exposure reductions and potential health impacts. Further research is also needed to understand the dose-response relationships and threshold effects for various toxicants.

Summary updated

Abstract

ISRCTN14301360 and UMIN000024988.
BibTeX
@inproceedings{gale2018changes,
  author = {Nathan Gale and Michael McEwan and Alison Eldridge and Ian M. Fearon and N. Sherwood and Edward Bowen and Simon McDermott and Emma Holmes and Andrew Hedge and Stuart Hossack and Louise Wakenshaw and James Glew and Oscar M. Camacho and Graham Errington and John McAughey and James J. Murphy and Chuan Liu and Christopher Proctor},
  title = {{Changes in Biomarkers of Exposure on Switching From a Conventional Cigarette to Tobacco Heating Products: A Randomized, Controlled Study in Healthy Japanese Subjects}},
  booktitle = {Nicotine},
  year = {2018},
  doi = {10.1093/ntr/nty104},
}
Figure